THE INCIDENCE, MORTALITY, AND SURVIVAL OF MALIGNANT BILIARY TRACT CANCER IN THE UNITED STATES: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) 2000-2023 DATABASE ANALYSIS
Author(s)
Filip Stanicic, PhD (c), Dimitrije Grbic, PhD (c), Vlad Zah, PhD.
Health Economist, ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
Health Economist, ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
OBJECTIVES: Investigating the disease burden of biliary tract cancer (BTC) in US population using updated Surveillance, Epidemiology, and End Results (SEER) data (released April 2026).
METHODS: SEER*Stat was used to analyze data from 21 cancer registries (2000-2023). Patients with BTC were identified using ICD-O-3 codes for cholangiocarcinoma, Klatskin tumor (KT), bile duct cystadenocarcinoma (BDC), and combined hepatocellular carcinoma and cholangiocarcinoma (CHCC). Only malignant cases were included. Assessed outcomes were incidence and mortality (crude rates per 100,000 population) and survival (1-year and 5-year rates). Incidence and mortality trends were reported as annual percent change (APC), calculated using the weighted least squares method.
RESULTS: The final sample had 69,292 patients, with 91.9% of them having cholangiocarcinoma. Patients were predominantly males (51.7%), elderly (64.5%), Non-Hispanic Whites (61.8%), metropolitan residents (88.8%), and 48.5% had $65,000-$90,000 annual household income (AHI). BTC incidence was 2.027 per 100,000 US population. The highest rates across categories were 1.862 for cholangiocarcinoma, 10.037 among elderly (65+ years), 2.121 among males, 2.380 among Non-Hispanic Asians/Pacific Islanders, 2.138 among non-metropolitan residents, and 2.363 among $120,000+ AHI. Significantly increasing trends were observed for cholangiocarcinoma (APC 6.093) and CHCC (APC 3.332), while KT showed a decreasing trend (APC -4.312). BTC mortality was 1.746 in the US. Across categories, the highest rates were reported for cholangiocarcinoma (1.601), males (1.841), Non-Hispanic Whites (2.017), non-metropolitan residents (1.892), and $120,000+ AHI (2.076). Significantly increasing trends were observed for cholangiocarcinoma (APC 6.303) and CHCC (APC 3.843), while KT had decreasing trend (APC -3.623). The highest survival had BDC (1-year 70.3%, 5-year 53.9%). The lowest rates were reported for cholangiocarcinoma (1-year 37.4%, 5-year 8.8%) and KT (1-year 30.5%, 5-year 5.5%).
CONCLUSIONS: The findings demonstrated significant real-world BTC burden in the US population. Cholangiocarcinoma was the most common subtype with increasing incidence and mortality trends alongside low survival rates.
METHODS: SEER*Stat was used to analyze data from 21 cancer registries (2000-2023). Patients with BTC were identified using ICD-O-3 codes for cholangiocarcinoma, Klatskin tumor (KT), bile duct cystadenocarcinoma (BDC), and combined hepatocellular carcinoma and cholangiocarcinoma (CHCC). Only malignant cases were included. Assessed outcomes were incidence and mortality (crude rates per 100,000 population) and survival (1-year and 5-year rates). Incidence and mortality trends were reported as annual percent change (APC), calculated using the weighted least squares method.
RESULTS: The final sample had 69,292 patients, with 91.9% of them having cholangiocarcinoma. Patients were predominantly males (51.7%), elderly (64.5%), Non-Hispanic Whites (61.8%), metropolitan residents (88.8%), and 48.5% had $65,000-$90,000 annual household income (AHI). BTC incidence was 2.027 per 100,000 US population. The highest rates across categories were 1.862 for cholangiocarcinoma, 10.037 among elderly (65+ years), 2.121 among males, 2.380 among Non-Hispanic Asians/Pacific Islanders, 2.138 among non-metropolitan residents, and 2.363 among $120,000+ AHI. Significantly increasing trends were observed for cholangiocarcinoma (APC 6.093) and CHCC (APC 3.332), while KT showed a decreasing trend (APC -4.312). BTC mortality was 1.746 in the US. Across categories, the highest rates were reported for cholangiocarcinoma (1.601), males (1.841), Non-Hispanic Whites (2.017), non-metropolitan residents (1.892), and $120,000+ AHI (2.076). Significantly increasing trends were observed for cholangiocarcinoma (APC 6.303) and CHCC (APC 3.843), while KT had decreasing trend (APC -3.623). The highest survival had BDC (1-year 70.3%, 5-year 53.9%). The lowest rates were reported for cholangiocarcinoma (1-year 37.4%, 5-year 8.8%) and KT (1-year 30.5%, 5-year 5.5%).
CONCLUSIONS: The findings demonstrated significant real-world BTC burden in the US population. Cholangiocarcinoma was the most common subtype with increasing incidence and mortality trends alongside low survival rates.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EPH183
Topic
Clinical Outcomes, Epidemiology & Public Health, Real World Data & Information Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology, Urinary/Kidney Disorders